158 related articles for article (PubMed ID: 22562379)
1. Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.
Moeller I; Spagnoli GC; Finke J; Veelken H; Houet L
Cancer Immunol Immunother; 2012 Nov; 61(11):2079-90. PubMed ID: 22562379
[TBL] [Abstract][Full Text] [Related]
2. Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens.
Liu X; Song N; Liu Y; Liu Y; Li J; Ding J; Tong Z
Cell Immunol; 2015 Jun; 295(2):77-82. PubMed ID: 25863743
[TBL] [Abstract][Full Text] [Related]
3. Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.
von Euw EM; Barrio MM; Furman D; Bianchini M; Levy EM; Yee C; Li Y; Wainstok R; Mordoh J
J Transl Med; 2007 Apr; 5():19. PubMed ID: 17448240
[TBL] [Abstract][Full Text] [Related]
4. Calreticulin acts as an adjuvant to promote dendritic cell maturation and enhances antigen-specific cytotoxic T lymphocyte responses against non-small cell lung cancer cells.
Liu X; Li J; Liu Y; Ding J; Tong Z; Liu Y; Zhou Y; Liu Y
Cell Immunol; 2016 Feb; 300():46-53. PubMed ID: 26702740
[TBL] [Abstract][Full Text] [Related]
5. Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene.
Lin L; Wei J; Chen Y; Huang A; Li KK; Zhang W
J Cancer Res Clin Oncol; 2014 Feb; 140(2):281-9. PubMed ID: 24322180
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications.
Spisek R; Charalambous A; Mazumder A; Vesole DH; Jagannath S; Dhodapkar MV
Blood; 2007 Jun; 109(11):4839-45. PubMed ID: 17299090
[TBL] [Abstract][Full Text] [Related]
7. Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation.
Birkholz K; Schwenkert M; Kellner C; Gross S; Fey G; Schuler-Thurner B; Schuler G; Schaft N; Dörrie J
Blood; 2010 Sep; 116(13):2277-85. PubMed ID: 20566893
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
[TBL] [Abstract][Full Text] [Related]
9. Dendritic cells loaded with myeloma cells pretreated with a combination of JSI-124 and bortezomib generate potent myeloma-specific cytotoxic T lymphocytes in vitro.
Jung SH; Lee YK; Lee HJ; Choi NR; Vo MC; Hoang MD; Lim MS; Nguyen-Pham TN; Kim HJ; Lee JJ
Exp Hematol; 2014 Apr; 42(4):274-81. PubMed ID: 24407159
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
11. Anticancer effects of adenovirus-mediated calreticulin and melanoma-associated antigen 3 expression on non-small cell lung cancer cells.
Liu X; Sun N; Dong Y; Li J; Liu Y; Ren Y; Yang C; Zhang L; Zhou Y; Tong Z; Ding J; Zhao X; Liu Y; He R; Xu K; Wu Y; Huang Y; Wang H; Tao X; Liu Y
Int Immunopharmacol; 2015 Apr; 25(2):416-24. PubMed ID: 25704851
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.
Kim JE; Jin DH; Lee WJ; Hur D; Wu TC; Kim D
Pharmacol Res; 2013 May; 71():23-33. PubMed ID: 23428347
[TBL] [Abstract][Full Text] [Related]
13. TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.
Straetemans T; van Brakel M; van Steenbergen S; Broertjes M; Drexhage J; Hegmans J; Lambrecht BN; Lamers C; van Der Bruggen P; Coulie PG; Debets R
Clin Dev Immunol; 2012; 2012():586314. PubMed ID: 22400038
[TBL] [Abstract][Full Text] [Related]
14. MAGE-A3 with cell-penetrating domain as an efficient therapeutic cancer vaccine.
Batchu RB; Gruzdyn O; Potti RB; Weaver DW; Gruber SA
JAMA Surg; 2014 May; 149(5):451-7. PubMed ID: 24671426
[TBL] [Abstract][Full Text] [Related]
15. Efficient presentation of known HLA class II-restricted MAGE-A3 epitopes by dendritic cells electroporated with messenger RNA encoding an invariant chain with genetic exchange of class II-associated invariant chain peptide.
Bonehill A; Heirman C; Tuyaerts S; Michiels A; Zhang Y; van der Bruggen P; Thielemans K
Cancer Res; 2003 Sep; 63(17):5587-94. PubMed ID: 14500399
[TBL] [Abstract][Full Text] [Related]
16. Chaetocin enhances dendritic cell function via the induction of heat shock protein and cancer testis antigens in myeloma cells.
Vo MC; Nguyen-Pham TN; Lee HJ; Jung SH; Choi NR; Hoang MD; Kim HJ; Lee JJ
Oncotarget; 2017 Jul; 8(28):46047-46056. PubMed ID: 28512265
[TBL] [Abstract][Full Text] [Related]
17. Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines.
de Carvalho F; Costa ET; Camargo AA; Gregorio JC; Masotti C; Andrade VC; Strauss BE; Caballero OL; Atanackovic D; Colleoni GW
PLoS One; 2011; 6(11):e27707. PubMed ID: 22110734
[TBL] [Abstract][Full Text] [Related]
18. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
19. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
20. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection.
Jonuleit H; Giesecke-Tuettenberg A; Tüting T; Thurner-Schuler B; Stuge TB; Paragnik L; Kandemir A; Lee PP; Schuler G; Knop J; Enk AH
Int J Cancer; 2001 Jul; 93(2):243-51. PubMed ID: 11410873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
